News

Individuals with cold agglutinin disease (CAD) face greater risks of mental health problems, with patients 60% more likely than healthy people to receive medical attention for anxiety or depression, according to a new U.S. study. The data referred to a combined risk of requiring either a hospital visit for…

People with cold agglutinin disease (CAD) reported clinically significant improvements in health-related quality of life after treatment with Enjaymo (sutimlimab-jome), according to a new analysis of data from the Phase 3 CADENZA clinical trial. These findings “further augment the primary efficacy outcomes of the placebo-controlled Phase 3 CADENZA…

Even with treatment, many people with cold agglutinin disease (CAD) continue to experience moderate or severe anemia and hemolysis events caused by red blood cell destruction, a new analysis found. “Despite high proportions of patients receiving CAD-related therapies during the first year following diagnosis, the number of moderate/severe anemia…

Enjaymo (sutimlimab-jome) has been approved by the European Commission (EC) to treat anemia caused by the loss of red blood cells — called hemolytic anemia — in adults with cold agglutinin disease (CAD). The EC’s decision to approve the therapy, the first and only approved therapeutic option for…

A woman with cold agglutinin disease (CAD) secondary to a cancer also developed bilateral retinal vasculitis — inflammation of the blood vessels found at the back of both eyes — in what researchers claim to be “the first report of retinal vasculitis in a patient with CAD.” Initial treatment…

A woman developed cold agglutinin disease (CAD), with high levels of cold agglutinins sustained for four months after symptom onset following a third dose of a vaccine for SARS-CoV-2, the virus that causes COVID-19, a case report from Japan. According to its authors, “the present case indicates…

Cold agglutinin disease (CAD) patients who take Enjaymo (sutimlimab-jome) long term may continue to experience disease remission after treatment discontinuation, according to a small study of three female patients. Two of the three women — all treated with Enjaymo for at least three years — showed no…

An enterovirus infection triggered autoimmune hemolytic anemia (AIHA) — a condition in which the body’s immune system generates self-reactive antibodies that destroy red blood cells — in an 11-year-old boy, a case study has reported for the first time. Although some signs were consistent with a case of virus-induced…

Global Genes and RARE-X, two nonprofit organizations dedicated to improving the lives of people with rare diseases like cold agglutinin disease (CAD), announced they are joining forces, with the merger expected to close by the end of this year. “What was apparent to all of us was how closely…

Although extremely rare, there have been cases of cold agglutinin disease (CAD) and related conditions following vaccination against COVID-19, a recent review study reported. While it’s difficult to draw firm conclusions about cause and effect, scientists say developing CAD may be a very rare side effect from COVID-19 vaccines.